Life sciences organizations today have a range of patient engagement approaches to choose from. However, when support is fragmented across access, marketing and patient services, it can lead to suboptimal patient experiences and outcomes.
In this Drug Channels Institute article, Chief Growth Officer Stacey Little discusses how advances in artificial intelligence (AI) are enabling a shift from a narrow focus on adherence to truly holistic patient engagement — and how the landscape will continue to evolve as healthcare becomes increasingly personalized.
Drug Channels Institute is one of the industry’s leading publications offering expert insights on pharmaceutical economics and the drug distribution systems.